rTMS in Promoting Smoking Cessation and Preventing Relapse in Current Smokers



Status:Recruiting
Healthy:No
Age Range:18 - 65
Updated:3/9/2019
Start Date:September 4, 2018
End Date:May 10, 2023

Use our guide to learn which trials are right for you!

Enhancing Relapse Prevention With rTMS: Dose-Response Parameters for Smoking Cessation

This trial studies best dose and how well repetitive transcranial magnetic stimulation (rTMS)
works in promoting smoking cessation and preventing relapse in current smokers. rTMS is a
form of brain stimulation therapy that controls nerve cell activity, increases blood flow in
the brain, and improves cognitive function.

PRIMARY OBJECTIVES:

I. To examine the effects of stimulation duration (stimulation days) and intensity (pulses
per day) on outcomes among smokers (sample size [n]=258) motivated to quit.

II. To identify the most promising dosing strategy by balancing effect sizes and undesirable
effects.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients undergo rTMS once daily (QD) or twice daily (BID) over 16 minutes for 8, 12,
or 16 days.

ARM II: Patients undergo sham rTMS QD or BID over 16 minutes for 8, 12, or 16 days.

Inclusion Criteria:

- Participants will be healthy right-handed adults

- Negative urine drug screen at the baseline assessment

- Ability to read at the 8th grade level

- Passes the Transcranial Magnetic Stimulation Adult Safety and Screening Questionnaire
(TASS)

- Participants must smoke between 5 and 25 cigarettes per day with the intent to quit
smoking in the next 30 days

- Participant or legal representative must understand the investigational nature of this
study and sign an Independent Ethics Committee/Institutional Review Board approved
written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

- Personal history of epilepsy

- History of anticonvulsant medication use

- Personal history of head injury

- History of aneurysm, stroke, or previous cranial neurosurgery or abnormal findings on
the magnetic resonance imaging (MRI) (e.g., tumor, aneurism, etc.)

- A diagnosis of major depressive disorder, bipolar disorder or a schizophrenia-spectrum
disorder, or tinnitus

- Metal implants or neuro-stimulators in the head, neck, or cochlea

- A pacemaker

- Migraine headaches

- Currently taking medications that lower seizure threshold (e.g., such as tricyclic
antidepressants or bupropion)

- Currently using medications for tobacco cessation (e.g., nicotine replacement,
bupropion, varenicline, etc?)

- Pregnant or planning to become pregnant in the next 24 weeks

- Current regular use of forms of tobacco other than cigarettes

- Participants who score above 48.3 on the Claustrophobia Questionnaire at the baseline
assessment will be excluded because they are likely to be unable to undergo an
magnetic resonance imaging (MRI) without distress

- Unwilling or unable to follow protocol requirements

- Any condition which in the Investigator?s opinion deems the participant an unsuitable
candidate to participate in the study
We found this trial at
1
site
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Christine Sheffer
Phone: 716-845-1186
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials